Aarey Drugs & Pharma Files SEBI Certificate for Q4FY26 Dematerialisation
Aarey Drugs & Pharmaceuticals Limited submitted a SEBI certificate for the quarter ended March 31, 2026. The certificate confirms dematerialisation processing by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
This is a standard regulatory filing related to share transfer and dematerialisation processes, which is a routine operational activity for listed companies. It does not involve any new financial information, strategic changes, or significant corporate actions that would impact the company's stock price or business operations.
The announcement is a routine compliance filing regarding the processing of securities dematerialisation and does not contain any material financial or business updates that would influence the company's valuation.
Aarey Drugs & Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate pertains to the quarter ended March 31, 2026.
This confirmation was received from M/s. MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent. MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the specified quarter were processed and the listed stock exchanges were updated accordingly. They also confirmed the cancellation of original certificates and substitution of the depository's name in the company's register of members within the prescribed timelines.
The company has requested that this information be taken on record.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.